9-27-16
They will be spilling the beans then and the bottom line will be like this:
"...At the core of Cellectar's value proposition is the company's proprietary Phospholipid Ether Drug Conjugate (PDC) Delivery Platform. The PDC Delivery Platform holds significant promise, having demonstrated selective targeting of cancer and cancer stem cells (CSC) in 70+ in vivo cancer models and on over 80 patients with 10+ types of cancer. With its targeted delivery, PDCs have the potential to improve the therapeutic index of drug payloads - maintaining and potentially enhancing efficacy, while reducing adverse events by minimizing drug delivery to healthy cells. If the company is successful in showing that PDCs can target multiple cancers and be effective with a variety of payloads, it should dramatically expand its potential in the $100+ billion cancer drug market."
"..."Cellectar's lead candidate using PDC is CLR-131, a Phase 1 candidate for the treatment of multiple myeloma. Cellectar intends for PDC to serve as a platform technology, which can be used to address many cancer types. We would expect the company to pursue a strategy in which it demonstrates the effectiveness of the platform with initial candidates covering a diverse group of payloads. Then we would expect Cellectar to advance new indications though strategic partnerships with larger pharmaceutical companies better equipped to fully fund new drug development. In our view, Cellectar is a speculative company in the biotechnology sector with the potential to develop and commercialize an impactful new cancer targeting and payload delivery technology in the large and growing market for oncology therapeutics," commented Ajay Tandon, CEO of SeeThruEquity. "We initiate coverage on Cellectar with a price target of $7.44."
